TAPI-2

• UNSPSC Description:

  TAPI-2 (TNF Protease Inhibitor 2) is a broad-spectrum inhibitor of matrix metalloprotease (MMP), tumour necrosis factorα-converting enzyme (TACE) and a disintegrin and metalloproteinase (ADAM), with an IC50 of 20 μM for MMP[1]. TAPI-2 blocks the entry of infectious SARS-CoV[2].

• Target Antigen:

  MMP; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/TAPI-2.html

• Purity:

  99.46

• Solubility:

  DMSO : ≥ 22 mg/mL|Ethanol : 50 mg/mL (warming)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CC(C)(C)[C@@H](C(N[C@H](C(NCCN)=O)C)=O)NC(C(CC(NO)=O)CC(C)C)=O

• Molecular Weight:

  415.53

• References & Citations:

  [1]Kruse MN, et al. Human meprin alpha and beta homo-oligomers: cleavage of basement membrane proteins and sensitivity to metalloprotease inhibitors. Biochem J. 2004 Mar 1;378(Pt 2):383-9.|[2]Wang R, et al. A Disintegrin and Metalloproteinase Domain 17 Regulates Colorectal Cancer Stem Cells and Chemosensitivity Via Notch1 Signaling. Stem Cells Transl Med. 2016 Mar;5(3):331-8.|[3]Shiori Haga, et al. TACE Antagonists Blocking ACE2 Shedding Caused by the Spike Protein of SARS-CoV Are Candidate Antiviral Compounds. Antiviral Res. 2010 Mar;85(3):551-5.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture and light)

• Clinical Information:

  No Development Reported

• CAS Number:

  187034-31-7